奥马珠单抗治疗复发性CRSwNP合并哮喘的短期疗效
该研究连续入组10例复发性慢性鼻窦炎伴鼻息肉合并哮喘患者,接受4个月奥马珠单抗治疗。结果显示鼻部症状VAS评分、SNOT-22评分、鼻息肉评分及外周血嗜酸粒细胞均较基线显著降低,鼻腔体积显著增大,提示奥马珠单抗可作为此类患者的替代治疗选择。
要点
- 奥马珠单抗治疗4个月可显著改善鼻塞、流涕、嗅觉减退和头痛症状。
- 治疗后可显著缩小鼻息肉体积并降低外周血嗜酸粒细胞计数和百分比。
- 奥马珠单抗可作为复发性CRSwNP合并哮喘患者的替代治疗选择。
核心结论
- 奥马珠单抗治疗4个月可明显改善合并哮喘的复发性CRSwNP患者的鼻部症状和生活质量。
- 奥马珠单抗可缩小鼻息肉体积并降低外周血嗜酸粒细胞数量,可作为该类患者新的治疗选择。
研究设计与样本
- 连续入组2020年5—12月就诊于首都医科大学附属北京同仁医院门诊的合并哮喘的复发性CRSwNP患者10例,男3例、女7例,年龄(41.13±12.64)岁。
- 患者接受4个月稳定背景治疗加奥马珠单抗治疗,于基线和用药第1、2、3、4个月访视收集鼻部症状VAS评分、SNOT-22评分及鼻息肉评分,于基线和第4个月收集血常规及鼻功能等客观检查。
- 使用GraphPad Prism 8.2.1进行统计学分析。
主要发现
- 治疗4个月后鼻塞VAS评分从基线(6.70±2.83)分降至(1.80±1.48)分,t=5.045,P<0.01。
- 治疗4个月后流涕VAS评分从基线(6.40±3.44)分降至(2.40±1.27)分,t=4.243,P<0.01;嗅觉减退从(8.20±2.25)分降至(2.70±2.91)分,t=5.312,P<0.01;头痛从(3.60±2.72)分降至(0.60±1.08)分,t=3.402,P<0.01。
- 外周血嗜酸粒细胞计数从基线(360.00±210.80)×10^9/L降至(94.10±97.78)×10^9/L,t=3.678,P<0.05;百分比从(64.40±20.73)%降至(32.90±27.06)%,t=2.957,P<0.05。
- 距前鼻孔5 cm处鼻腔体积从基线(10.40±2.09)cm³增至(12.62±2.84)cm³,t=2.371,P<0.05;7 cm处从(16.81±6.40)cm³增至(27.50±14.15)cm³,t=2.445,P<0.05。
临床怎么用
- 对合并哮喘的复发性CRSwNP患者,可考虑使用奥马珠单抗治疗4个月以改善鼻部症状和生活质量。
- 治疗期间可监测鼻部症状VAS评分、SNOT-22评分、鼻息肉评分及外周血嗜酸粒细胞以评估疗效。
局限性
- 本研究为单中心、小样本(10例)自身前后对照研究,未设对照组。
- 随访时间仅4个月,仅评估短期疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the short-term efficacy of anti-IgE monoclonal antibody (Omalizumab) in the treatment of recurrent chronic rhinosinusitis with nasal polyps (CRSwNP) complicated with asthma. Methods: Patients with recurrent CRSwNP and comorbid asthma in Beijing TongRen Hospital from May to December of 2020 were continuously recruited and received a 4-month therapy of stable background treatment plus Omalizumab. Results of visual analog scales (VAS) of nasal symptoms, sino-nasal outcome test-22 (SNOT 22) and nasal polyp scores were collected at baseline and post-treatment (1, 2, 3 and 4 months after treatment). Blood routine tests, total nasal resistances (TNR), minimum cross-sectional areas (MCA), total nasal cavity volumes (NCV), forced expiratory volumes in one second (FEV1)/forced vital capacity (FVC) and adverse events were collected at baseline and 4 months after treatment. All results were evaluated for short-term efficacy of Omalizumab. GraphPad Prism 8.2.1 was used for statistic analysis. Results: Ten patients were collected, including 3 males and 7 females, aged (41.13±12.64) years old (x¯±s). Compared to results at baseline, the VAS scores of nasal obstruction, rhinorrhea, hyposmia and headache after 4 months treatment were significantly decreased (1.80±1.48 vs 6.70±2.83, 2.40±1.27 vs 6.40±3.44, 2.70±2.91 vs 8.20±2.25, 0.60±1.08 vs 3.60±2.72, t value was 5.045, 4.243, 5.312, 3.402, respectively, all P<0.01). The scores of SNOT-22 (25.6±20 vs 61.3±33.32, t=4.127, P=0.002 6), nasal polyp scores (2.20±0.92 vs 4.60±0.84, t=9.000, P<0.01) and the count and percentage of eosinophils in peripheral blood were significantly decreased ((94.10±97.78)×109/L vs (360.00±210.80)×109/L, (32.90±27.06)% vs (64.40±20.73)%, t value was 3.678, 2.957, respectively, all P<0.05). NCV (0-5 cm and 0-7 cm) of patients were improved from baseline ((12.62±2.84) cm3 vs (10.40±2.09) cm3, (27.50±14.15) cm3 vs (16.81±6.40) cm3, t value was 2.371, 2.445, respectively, all P<0.05). Conclusions: The 4-month treatment of Omalizumab can significantly improve the nasal symptoms and quality of life of patients with recurrent CRSwNP complicated with asthma, shrink nasal polyps size and reduce the number of peripheral blood eosinophils. Omalizumab can be used as an alternative therapy for refractory CRSwNP patients in the future. 目的: 探究抗IgE单克隆抗体(奥马珠单抗)治疗合并哮喘的复发性慢性鼻窦炎伴鼻息肉(CRSwNP)患者的短期疗效。 方法: 2020年5—12月,连续入组就诊于首都医科大学附属北京同仁医院门诊的合并哮喘的复发性CRSwNP患者。使用奥马珠单抗治疗4个月,在基线和用药第1、2、3、4个月访视时,收集患者鼻部症状视觉模拟量表(VAS)评分、鼻腔鼻窦结局测试22(SNOT-22)评分及鼻息肉评分等;在基线和用药第4个月访视时,收集患者血常规、鼻功能等客观检查结果。对用药后鼻部症状评分及客观检查结果较基线的变化差异进行分析,评估奥马珠单抗治疗的短期疗效。使用GraphPad Prism 8.2.1进行统计学分析。 结果: 共收集符合条件的患者10例,其中男3例,女7例,年龄(41.13±12.64)岁(x¯±s)。经过4个月奥马珠单抗治疗后,患者鼻塞、流涕、嗅觉减退、头痛VAS评分较基线显著降低[(1.80±1.48)分比(6.70±2.83)分,(2.40±1.27)分比(6.40±3.44)分,(2.70±2.91)分比(8.20±2.25)分,(0.60±1.08)分比(3.60±2.72)分,t值分别为5.045、4.243、5.312、3.402,P值均<0.01];SNOT-22评分较基线显著降低[(25.60±20.00)分比(61.30±33.32)分,t=4.127,P=0.002 6];鼻息肉评分较基线显著降低[(2.20±0.92)分比(4.60±0.84)分,t=9.000,P<0.01];外周血嗜酸粒细胞计数、百分比均较基线显著降低[(94.10±97.78)×109/L比(360.00±210.80)×109/L,(32.90±27.06)%比(64.40±20.73)%,t值分别为3.678、2.957,P值均<0.05];鼻腔体积(距前鼻孔5 cm和7 cm处)均较基线有显著增大[(12.62±2.84)cm3比(10.40±2.09)cm3,(27.50±14.15)cm3比(16.81±6.40)cm3,t值分别为2.371、2.445,P值均<0.05]。 结论: 使用奥马珠单抗治疗4个月可明显改善合并哮喘的复发性CRSwNP患者的鼻部症状、生活质量,缩小鼻息肉体积,降低外周血嗜酸粒细胞数量,可作为该类患者新的治疗选择。.
引用
- Shen S, Lou HF, Yan B, et al. [Short-term efficacy of anti-IgE monoclonal antibody in patients with recurrent chronic rhinosinusitis with nasal polyps combined with asthma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2021. PMID: 34666463. doi:10.3760/cma.j.cn115330-20210608-00338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。